Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “”. Supporting the 2022 Sustainability Report is a document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).
Tony Hunt, Chief Executive Officer at Repligen said, “Our initial Sustainability report published in 2021 elevated awareness in the company and prompted higher levels of action across the ESG spectrum. We saw strong ratings and rankings as a result and are pleased to share this next 2022 progress report, while continuing to work toward positively impacting some of our more challenging initiatives and collaboration-based goals.”
Dianne Heiler, Senior Director of Packaging and Head of Sustainability at Repligen said, “I’m proud to be part of the team at Repligen that is driving progress across multiple sustainability ambitions, with the full support and participation of our executive team and Board. As this report publishes, already we are expanding the scope of our efforts and will submit a commitment letter by year end 2023 to SBTi* to lower total GHG emissions in alignment with the latest climate science.”
Below are just a few of the 2022 Sustainability Report highlights. Report data is through year end 2022 unless otherwise noted.
Environmental impacts:
- Reduced greenhouse gas (GHG) emissions intensity by 40% since year end 2020.
- Transitioned to 100% renewable energy at 9 of 18 sites representing 75% of our global consumption.
- Added Scope 3 emissions tracking and benchmarking for 9 of 15 GHG Protocol categories.
Social impacts:
- Advanced workplace diversity:
- New hires: In 2022, 41% of Manager level (Associate Director and above) new hires were Women (global), and 37% were People of Color (U.S.).
- Overall: At year end 2022, 27% of Managers were Women, compared to 22% in 2020, and 26% of Managers were People of Color, compared to 20% in 2020.
Governance impacts:
- Fortified our cybersecurity systems and protocols, implemented a Zero Trust framework.
- Updated our charters and policies to maintain strong governance practices, including shareholder proxy access.
Survey participation:
- In 2023, we completed our first CDP Climate survey and CDP Water survey, each for the year 2022.
- In 2022, a pilot study of 12% our Tier 1 suppliers completed sustainability surveys by our request, to help build our Scope 3 emissions inventory. In addition, we completed over one dozen sustainability surveys by request of our customers.
*SBTi: Science Based Targets initiative
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visit , and follow us on .
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
